Navigation Links
United BioSource Expands Regulatory Affairs Capabilities
Date:2/25/2008

Former Pfizer executives to lead regulatory affairs group based in Ann

Arbor, Michigan

BETHESDA, Md., Feb. 25 /PRNewswire/ -- United BioSource Corporation (UBC) today announced the expansion of its Regulatory Affairs group led by distinguished experts Mark Ammann, Pharm.D. and LaVonne Lang, Dr PH. Based in Ann Arbor, Michigan, the group will provide a full range of services to pharmaceutical and biotechnology clients, including creating and implementing development plans to fulfill regulatory requirements for initial approval of new medicines and providing life-cycle management for marketed products.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070910/NEM007LOGO )

The Regulatory Affairs group will be headed by Dr. Mark Ammann, a 17-year veteran of the pharmaceutical industry, who has worked with products from early development to post-marketing product support in such diverse therapeutic areas as CNS, oncology, dermatology, inflammation, endocrinology and cardiovascular disorders. Dr. Ammann most recently held the position of Global Head of Regulatory Affairs at Pfizer Corporation where he was responsible for several therapeutic areas including central nervous system, inflammation and dermatology.

"We are thrilled to welcome Dr. Ammann and Dr. Lang to the UBC team. They give us world-class experience and expertise in navigating through the drug development process with the FDA. This capability complements our specialized regulatory knowledge in areas like health outcomes and post-approval research to provide clients unique regulatory insight in both the pre- and post- approval environment," according to Ethan Leder, UBC CEO and Founder.

"Having led many interactions with the FDA over the past 16 years, I am particularly excited about helping clients navigate through the maze of evolving regulations, offering them counsel about the impact of these changes to their programs," says Dr. Ammann.

Dr. LaVonne Lang will join Ammann in a leadership role, serving as Senior Director, Regulatory Affairs. Dr. Lang has 18 years of experience in pharmaceutical development, with 12 years in positions of increasing responsibility in regulatory strategy at Parke-Davis and Pfizer.

The group will conduct cradle-to-grave global strategic planning, manage submission and liaison activities with health authorities and handle medical writing of regulatory documents. As part of its mandate, they will offer services to both emerging and established life science companies.

United BioSource Corporation (UBC) is a global pharmaceutical services organization that helps emerging and established life science companies develop and commercialize medical products. UBC specializes in offering new and innovative ways to study drugs and devices by offering expertise in science, strategy and execution.

UBC is headquartered in Bethesda, Maryland, with offices in the United States, Canada, Eastern and Western Europe and South America. For more information, visit http://www.unitedbiosource.com or call 866-458-1096.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Mark Ammann, PharmD http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=73619 LaVonne Lang, Dr PH http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=73620


'/>"/>
SOURCE United BioSource Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
2. United States Patent Office Grants CryoCors Request for Patent Interference
3. United Therapeutics to Announce Fourth Quarter and Annual 2007 Financial Results Before Market Open on Tuesday, February 19, 2008
4. Energy Conversion Devices and United Solar Ovonic Enter Into New $55 Million Secured Credit Facility Agreements
5. Nycomeds Ciclesonide to be Commercialised in the United States by Sepracor
6. Chindexs United Family Hospitals and Clinics and NBC Enter into Healthcare Services Agreement
7. Neptune Technologies receives GRAS notification in the United States
8. Essilor: New Acquisitions in the United States and Brazil
9. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
10. Medical Services Begins Working With United States Companies for Distribution of Its Products
11. United Therapeutics Reports Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... NEW YORK , June 22, 2016 /PRNewswire/ ... the growing next generation sequencing (NGS) market include ... adoption of smaller sequencers.  More accessible and affordable ... led to growing demand for consumables including sample ... The Market for Sample Preparation for Next ...
(Date:6/22/2016)... , June 22, 2016   ViaCyte, Inc. , ... stem cell-derived islet replacement therapy for the treatment of ... ISSCR 2016 Annual Meeting.  ISSCR 2016, the Global Stem ... at Moscone West in San Francisco.  ... presentations are as follows:Event: , Focus Session: Tools for ...
(Date:6/22/2016)... 2016  Mesa Biotech Inc., a privately-held, molecular ... designed specifically for point-of-care (POC) infectious disease diagnosis, ... board (SAB). Approved by the executive leadership team ... to advise on the development and commercialization of ... Dr. Steve Young , this world-class team ...
(Date:6/21/2016)... NANJING , China , June ... that a Phase 2 clinical trial for its novel ... statistically significant (p=0.023) and clinically meaningful pain relief against ... the United States , the trial enrolled 146 ... statistically significant (1) analgesia against placebo at week-1 (p=0.024), ...
Breaking Biology Technology:
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
Breaking Biology News(10 mins):